277 related articles for article (PubMed ID: 23257677)
1. [Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].
Fuchida S; Okano A; Hatsuse M; Murakami S; Haruyama H; Shimazaki C
Rinsho Ketsueki; 2012 Nov; 53(11):1937-9. PubMed ID: 23257677
[TBL] [Abstract][Full Text] [Related]
2. [Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma].
Taniguchi H; Imaizumi Y; Makiyama J; Ando K; Sawayama Y; Imanishi D; Taguchi J; Tsushima H; Hata T; Miyazaki Y
Rinsho Ketsueki; 2014 Aug; 55(8):953-7. PubMed ID: 25186485
[TBL] [Abstract][Full Text] [Related]
3. [Successful treatment with thalidomide-combined therapy in an amyloidosis-complicated multiple myeloma patient refractory to bortezomib, lenalidomide, and pomalidomide].
Aoki Y; Hayashi T; Ikeda H; Ishida T
Rinsho Ketsueki; 2018; 59(3):275-280. PubMed ID: 29618684
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Nagano S; Mori M; Kato A; Ono Y; Aoki K; Arima H; Takiuchi Y; Tabata S; Yanagita S; Matsushita A; Ishikawa T; Imai H; Takahashi T
Intern Med; 2013; 52(10):1101-5. PubMed ID: 23676598
[TBL] [Abstract][Full Text] [Related]
5. [Fatal hepatic failure due to AL amyloidosis in a patient with multiple myeloma].
Tabata S; Kurata M; Takeda J; Funayama Y; Yamauchi N; Aoki K; Kato A; Ono Y; Arima H; Takiuchi Y; Nagano S; Matsushita A; Imai Y; Ishikawa T; Takahashi T
Rinsho Ketsueki; 2012 Nov; 53(11):1906-10. PubMed ID: 23257671
[TBL] [Abstract][Full Text] [Related]
6. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
10. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
[TBL] [Abstract][Full Text] [Related]
11. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
13. Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
Asou N; Izuno Y; Okubo T; Ide K; Ueno H; Kawakita M; Mitsuya H; Hata H
Int J Hematol; 2007 Jul; 86(1):69-71. PubMed ID: 17675270
[TBL] [Abstract][Full Text] [Related]
14. [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
Higeta D; Yokohama A; Osaki Y; Tahara K; Mawatari M; Sekigami T; Koiso H; Saito T; Uchiumi H; Handa H; Karasawa M; Murakami H; Hirato J; Tsukamoto N; Nojima Y
Rinsho Ketsueki; 2009 Dec; 50(12):1711-4. PubMed ID: 20068279
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
Sanchorawala V; Wright DG; Rosenzweig M; Finn KT; Fennessey S; Zeldis JB; Skinner M; Seldin DC
Blood; 2007 Jan; 109(2):492-6. PubMed ID: 16960148
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of multiple myeloma--associated amyloidosis by interferon-alpha, dimethyl sulfoxide, and VAD (vincristine, adriamycin, and dexamethasone).
Ichida M; Imagawa S; Ohmine K; Komatsu N; Hatake K; Ozawa K; Miura Y
Int J Hematol; 2000 Dec; 72(4):491-3. PubMed ID: 11197218
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
19. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
